Table 2.
Most common diagnoses reported for each single-gene pharmacogenetic test of interesta.
| Diagnosis reported on pharmacogenetic test claim | CYP2C19 (N = 4719) N (%) | CYP2D6 (N = 3775) N (%) | CYP2C9 (N = 3289) N (%) | HLA class 1 (N = 1821) N (%) | VKORC1 (N = 1587) N (%) | UGT1A1 (N = 191) N (%) |
|---|---|---|---|---|---|---|
| Long-term (current) use of medications | 966 (20.5%) | 883 (23.4%) | 705 (21.4%) | 110 (6.0%) | 534 (33.7%) | 48 (25.1%) |
| Depression | 976 (20.1%) | 940 (24.9%) | 826 (25.1%) | 507 (27.8%) | 165 (10.4%) | 25 (13.1%) |
| Anxiety | 622 (13.2%) | 592 (15.7%) | 523 (15.9%) | 299 (16.4%) | 117 (7.4%) | 32 (16.8%) |
| Lipid disorders | 664 (14.1%) | 221 (5.8%) | 228 (6.9%) | 73 (4.0%) | 204 (12.8%) | 15 (7.8%) |
| Hypertension | 563 (11.9%) | 310 (8.2%) | 310 (9.4%) | 43 (2.4%) | 293 (18.5%) | 29 (15.2%) |
| Pain/low back pain | 436 (9.2%) | 440 (11.7%) | 389 (11.8%) | 41 (2.2%) | 238 (15.0%) | 58 (30.4%) |
| ADHD | 515 (10.9%) | 519 (13.8%) | 460 (14.0%) | 301 (16.5%) | 53 (3.3%) | 25 (13.1%) |
| HIV | 0 | 0 | 0 | 544 (29.9%) | 0 | 0 |
ADHD attention deficit–hyperactivity disorder.
aTop three diagnoses for each test are indicated in italics.